Phase 3 Depression and Anxiety Trial, Recruiting NCT05772104 Sponsor: Sichuan Jishengtang Pharmaceutical Co., Ltd. Condition: Depression and Anxiety
Back to Depression And Anxiety

Phase 3 Depression and Anxiety Trial, Recruiting

NCT05772104
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been formally diagnosed with Generalised Anxiety Disorder (GAD), with symptoms lasting for at least 6 months
  • People between 18 and 65 years of age
  • People whose anxiety symptoms score at or above a certain level on two standard anxiety rating scales, measured at two separate appointments before the trial begins
  • People whose anxiety is assessed as being at least moderately severe by a clinician at both pre-trial appointments
  • People whose anxiety pattern matches a specific Traditional Chinese Medicine (TCM) profile described as "liver Qi stagnation and spleen deficiency syndrome" (confirm with trial site)

Who may not be able to join:

  • People who have been diagnosed with another mental health condition (other than GAD) in the 6 months before screening
  • People who have had problems with alcohol or drug misuse or dependence in the 6 months before screening, or whose urine drug test at screening comes back positive
  • People whose depression symptoms score too highly on a standard depression rating scale at either pre-trial appointment
  • People who have severe insomnia

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Gang Wang, MD, Beijing Anding Hospital Affiliated to Capital Medical University

Phone: 028-81258178

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Sichuan Jishengtang Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
17 April 2023
Est. completion
28 February 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change From Baseline in the HAM-A Total Score at Week 12

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov